USP and Brazil Partner on Public Health Education - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

USP and Brazil Partner on Public Health Education

ePT--the Electronic Newsletter of Pharmaceutical Technology

The US Pharmacopeia (USP) continues to expand its collaboration with drug authorities around the world, this time with Brazil’s regulatory agency. USP and the Brazilian National Agency of Sanitary Surveillance (ANVISA) are teaming up to develop joint education activities for professionals involved in formulating and using pharmacopeial monograph standards in Brazil, according to news releases on the USP website.

“The organizations [are] committed to work together in developing joint education activities for professionals involved in formulating and using pharmacopeial monograph standards,” says a USP release. “The agreement acknowledges that both organizations share common goals for improving public health related to quality medicines through education.”

In addition to drug regulation, ANVISA oversees the Brazilian Pharmacopeia. The agency has offices in São Paulo as well as in the United States. Products manufactured in Brazil and sold into the US market must meet USP standards, which are enforceable by FDA.

According to Dr. Dirceu Barbano, director-president of ANVISA, “With Brazil’s continuing emergence as a center for global pharmaceutical manufacturing, cooperative efforts with organizations like USP will help to refine and strengthen our capabilities in ensuring good quality medicines and their ingredients,” he stated in the USP news release [see Brazil’s perspective in a recent PharmTech blog post].

As part of the educational activities, USP and ANVISA plan to:

  • Increase awareness of the quality, safety, and efficacy of medicines and foods
  • Promote cooperation between the organizations to improve the quality of medicines and foods
  • Improve the exchange of information, including scientific and technological knowledge that may contribute to research and teaching
  • Facilitate the harmonization of pharmacopeial standards
  • Establish a basis and mechanism for cooperation between the two parties.

Implementation of the agreement will involve leadership from USP’s facility in São Paulo and its global headquarters.

USP has expanded its international reach in recent years through drug-quality partnerships with other national drug authorities, such as that in Russia. The organization runs a program in collaboration with the US Agency for International Development called Promoting the Quality of Medicines (PQM). The program is aimed at helping to ensure the quality, safety, and efficacy of medicines essential to USAID priority diseases, particularly malaria, HIV/AIDS, and tuberculosis.

Of note, Hellen Berger reports on the Brazilian pharmaceutical industry in PharmTech’s September issue. Also in the upcoming September issue: a debate about USP’s international goals.

See Related Articles:

USP and Russia


USP and Developing Countries


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here